Literature DB >> 3805771

A prospective study of the epidemiology and ecology of Lassa fever.

J B McCormick, P A Webb, J W Krebs, K M Johnson, E S Smith.   

Abstract

In studies of Lassa fever in Sierra Leone, the prevalence of human antibody to Lassa virus ranged from 8% to 52%. Mastomys natalensis, the reservoir of Lassa virus, constituted 50%-60% of the rodents captured in houses but only 10%-20% of those captured in surrounding agriculture and bush areas (chi 2 = 90.2, P less than 10(-6), df = 1), a finding suggesting that houses are the most-important location for transmission of Lassa virus. Viral infection of Mastomys from houses ranged from 0% to 80%. The incidence of seroconversions in susceptible persons ranged from 5% to 22% per year; the ratio of illness to infection ranged from 9% to 26%, and the proportion of febrile illness associated with seroconversion was 5%-14%. Eightfold rises in titer of antibody occurred in 1%-18% of the antibody-positive population, a result suggesting reinfection. We estimate the ratio of fatalities to infection to be 1%-2%, a rate lower than estimates based on hospitalized cases. The high incidence of Lassa fever makes it a major problem in West Africa.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3805771     DOI: 10.1093/infdis/155.3.437

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  211 in total

1.  Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein.

Authors:  O Lenz; J ter Meulen; H Feldmann; H D Klenk; W Garten
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P.

Authors:  O Lenz; J ter Meulen; H D Klenk; N G Seidah; W Garten
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

3.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 4.  Lassa fever: epidemiology, clinical features, and social consequences.

Authors:  J Kay Richmond; Deborah J Baglole
Journal:  BMJ       Date:  2003-11-29

5.  Dissection of the role of the stable signal peptide of the arenavirus envelope glycoprotein in membrane fusion.

Authors:  Emily L Messina; Joanne York; Jack H Nunberg
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

6.  An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion.

Authors:  Joanne York; Jody D Berry; Ute Ströher; Qunnu Li; Heinz Feldmann; Min Lu; Meg Trahey; Jack H Nunberg
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

7.  Improved detection of Lassa virus by reverse transcription-PCR targeting the 5' region of S RNA.

Authors:  Stephan Olschläger; Michaela Lelke; Petra Emmerich; Marcus Panning; Christian Drosten; Meike Hass; Danny Asogun; Deborah Ehichioya; Sunday Omilabu; Stephan Günther
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

8.  Rapid detection of Lassa virus by reverse transcription-loop-mediated isothermal amplification.

Authors:  Aiko Fukuma; Yohei Kurosaki; Yuko Morikawa; Allen Grolla; Heinz Feldmann; Jiro Yasuda
Journal:  Microbiol Immunol       Date:  2011-01       Impact factor: 1.955

9.  Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.

Authors:  Chad E Mire; Robert W Cross; Joan B Geisbert; Viktoriya Borisevich; Krystle N Agans; Daniel J Deer; Megan L Heinrich; Megan M Rowland; Augustine Goba; Mambu Momoh; Mathew L Boisen; Donald S Grant; Mohamed Fullah; Sheik Humarr Khan; Karla A Fenton; James E Robinson; Luis M Branco; Robert F Garry; Thomas W Geisbert
Journal:  Nat Med       Date:  2017-09-04       Impact factor: 53.440

10.  Receptor use by the Whitewater Arroyo virus glycoprotein.

Authors:  Therese Reignier; Jill Oldenburg; Meg L Flanagan; Genevieve A Hamilton; Vanessa K Martin; Paula M Cannon
Journal:  Virology       Date:  2007-11-13       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.